RecruitingNCT02219984

START-Register: Survey on Anticoagulated Patients Register

Phase 4 Study on Clinical History of Patients Who Start a Chronic Anticoagulant Treatment


Sponsor

GUALTIERO PALARETI

Enrollment

15,410 participants

Start Date

Oct 1, 2011

Study Type

OBSERVATIONAL

Conditions

Summary

This is a phase 4 cohort prospective, open, national, multicentre study that collects data on history of patients treated chronically with anticoagulant drugs, including the novel direct oral anticoagulants (DOACs). The Registry is designed solely for observational purposes and is not intended to have any influence on the treatment of the single patients included. Patients are included when they start the anticoagulant treatment, whatever the drug used, or when they shift from a vitamin K antagonist (VKA) drug to one of the novel direct oral anticoagulants, provided that the therapy is expected to last at least 3 months. The general aims of the study are to provide a better evaluation of efficacy and safety of different treatment options, and to improve our understanding of the risks/benefits of the various anticoagulant drugs and the different therapy options. The Registry is open to the participation of clinical centres or individual professionals (now called Participants) that are involved with management of anticoagulated patients.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is the START Register — a large observational registry that collects real-world data from patients who are taking anticoagulant medications (commonly called blood thinners, such as warfarin, rivaroxaban, or apixaban). The study tracks how these medications are prescribed, how patients use them, what complications arise (such as bleeding or blood clots), and what long-term health outcomes patients experience. This information helps improve prescribing practices and patient safety. **You may be eligible if...** - You are 18 or older - You are currently being treated with an anticoagulant medication (a blood thinner prescribed to prevent or treat blood clots) - You are willing and able to sign an informed consent form **You may NOT be eligible if...** - You are under 18 years of age - You are not willing to sign the required informed consent form Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAnticoagulants

Locations(1)

S. Orsola-Malpighi University hospital

Bologna, BO, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02219984


Related Trials